2-Piperazinyl-6,7-dimethoxyquinazolines
AssigneeMead Johnson & Company
InventorsWilliam Lesley Matier, John David Catt
Life of this patent
Estimating the term…
Abstract
A series of novel 4-amino or 4-hydrazino-2-(substituted piperazinyl)-6,7-dimethoxyquinazolines is disclosed having antihypertensive and phosphodiesterase inhibiting properties. Piperazinyl substituents include cycloalkenylcarbonyl, cycloalkylcarbonyl, and methylcycloalkylcarbonyl. A representative embodiment of the invention is 4-amino-2-[4-(cyclopentylcarbonyl)-1-piperazinyl]-6,7-dimethoxyquinazoline .
Claims19
A compound having the formula ##STR11## or a pharmaceutically acceptable salt thereof wherein R is amino or hydrazino;
- R.sub.1 is cycloalkyl having 3 to 8 ring carbon atoms inclusive and cycloalkenyl having 4 to 8 ring carbon atoms inclusive.
A process for treating hypertension which comprises systemically administering to a mammal in need of said treatment an antihypertensive effective amount of a compound having the formula ##STR12## or a pharmaceutically acceptable salt thereof wherein R is amino or hydrazino;
- R.sub.1 is cycloalkyl having 3 to 8 ring carbon atoms inclusive and cycloalkenyl having 4 to 8 ring carbon atoms inclusive.
A pharmaceutical composition in dosage unit form adapted for the systemic administration to a mammal comprising a dose of from 0.001 to 50 mg. per kilogram of body weight of said mammal of a compound having the formula ##STR13## or a pharmaceutically acceptable salt thereof wherein R is amino or hydrazino;
- R.sub.1 is cycloalkyl having 3 to 8 ring carbon atoms inclusive and cycloalkenyl having 4 to 8 ring carbon atoms inclusive.
The compound 4-amino-6,7-dimethoxy-2-[4-[(1-methylcyclohexyl)carbonyl]-1-piperazinyl]qu inazoline.
Dependencies are inferred from the claim text.